Literature DB >> 1607148

What is congenital hepatic fibrosis?

V J Desmet1.   

Abstract

The hypothesis presented in this paper suggests that, at birth, the basic lesion of congenital hepatic fibrosis corresponds to ductal plate malformation of interlobular bile ducts, resulting from faulty development, i.e. disturbance in epithelio-mesenchymal inductive interactions. The immature bile ducts are subject to a progressive destructive cholangiopathy, resulting in a pattern of more or less advanced fetal type of biliary fibrosis. The destructive cholangiopathy may be of variable speed and duration in different patients. The renal lesions in autosomal recessive polycystic kidney disease, which is most often associated with congenital hepatic fibrosis, show a comparable pattern and evolution. The hypothesis that congenital hepatic fibrosis corresponds to a fetal type of biliary fibrosis would explain a number of disparate observations. According to this concept, congenital hepatic fibrosis does not correspond to a single clinical entity but to a broad, merging spectrum of conditions. All have in common that they represent some stage of biliary fibrosis, usually of the fetal type, rarely of the adult type, resulting from a slowly progressive, destructive cholangiopathy.

Entities:  

Mesh:

Year:  1992        PMID: 1607148     DOI: 10.1111/j.1365-2559.1992.tb01031.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

1.  Congenital hepatic fibrosis in calves.

Authors:  A C Bourque; I C Fuentealba; R Bildfell; P Y Daoust; P Hanna
Journal:  Can Vet J       Date:  2001-02       Impact factor: 1.008

Review 2.  Liver and kidney disease in ciliopathies.

Authors:  Meral Gunay-Aygun
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-11-15       Impact factor: 3.908

Review 3.  Large-duct cholangiopathies: aetiology, diagnosis and treatment.

Authors:  Shyam Menon; Andrew Holt
Journal:  Frontline Gastroenterol       Date:  2019-01-04

4.  Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease.

Authors:  Meral Gunay-Aygun; Esperanza Font-Montgomery; Linda Lukose; Maya Tuchman Gerstein; Katie Piwnica-Worms; Peter Choyke; Kailash T Daryanani; Baris Turkbey; Roxanne Fischer; Isa Bernardini; Murat Sincan; Xiongce Zhao; Netanya G Sandler; Annelys Roque; Daniel C Douek; Jennifer Graf; Marjan Huizing; Joy C Bryant; Parvathi Mohan; William A Gahl; Theo Heller
Journal:  Gastroenterology       Date:  2012-10-03       Impact factor: 22.682

5.  Lhx2-/- mice develop liver fibrosis.

Authors:  Ewa Wandzioch; Asa Kolterud; Maria Jacobsson; Scott L Friedman; Leif Carlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-09       Impact factor: 11.205

Review 6.  Experience of a single center with congenital hepatic fibrosis: a review of the literature.

Authors:  Ali Shorbagi; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

7.  Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway.

Authors:  Miguel A Garcia-Gonzalez; Luis F Menezes; Klaus B Piontek; Junya Kaimori; David L Huso; Terry Watnick; Luiz F Onuchic; Lisa M Guay-Woodford; Gregory G Germino
Journal:  Hum Mol Genet       Date:  2007-06-16       Impact factor: 6.150

Review 8.  Caroli's syndrome in a post renal transplant patient: case report and review of the literature.

Authors:  Muhammad Z Bawany; Osama Alaradi; Ali Nawras
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

9.  Whole exome sequencing identifies recessive PKHD1 mutations in a Chinese twin family with Caroli disease.

Authors:  Xiwei Hao; Shiguo Liu; Qian Dong; Hong Zhang; Jing Zhao; Lin Su
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

10.  Central diabetes insipidus associated with Caroli syndrome.

Authors:  Semra Cetinkaya; Ayfer Alikasifoglu
Journal:  Indian J Pediatr       Date:  2007-04       Impact factor: 5.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.